EUVIMEDEUVIMED entdecken
EditorialOpen Access

Crossing borders: the need for empirical evidence of real-world evidence transportability in oncology

Caitlin Clunie-O'Connor, Per-Olof Thuresson, Elizabeth Masters, Aliki Taylor, Mats Rosenlund, Philani Mpofu, Blythe Adamson iD

Journal of Comparative Effectiveness Research · 2025

DOI: 10.57264/cer-2025-0053 ↗

Kurz gefasst

Editorial in der Zeitschrift Journal of Comparative Effectiveness Research, 2025. Verfasst von Caitlin Clunie-O'Connor und 6 weiteren Autor:innen. Beteiligte Einrichtung: Flatiron Health UK, London, UK. Hauptthemen laut MEDLINE: Technology Assessment, Biomedical, Medical Oncology, Neoplasms. Die Arbeit nennt 16 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Plain language summary What is this article about? This article discusses the challenges of using non local real-world evidence (RWE) in health technology assessments (HTA) when local data are unavailable, insufficient, or inappropriate. HTA organizations often prefer data collected locally or regionally, but the lack of suitable data in many markets has increased interest in understanding data ‘transportability’ – whether data from one country or population can be used to predict outcomes in another. Established in 2024, the Flatiron Fostering Oncology RWE Use Cases and Methods (FORUM) research consortium is exploring when and how non-local RWE can be effectively applied, with initial work focused on lung cancer, breast cancer and multiple myeloma. What does the evidence suggest so far? Initial studies suggest RWE from the US could predict outcomes in other countries with proper adjustment for population and treatment differences. Recent research in advanced non-small cell lung cancer demonstrated that adjusted US data provided comparable survival to real observed outcomes in Canada and the UK. This limited evidence base indicates that non-local RWE can help inform decision-making when local data is unavailable. What studies are needed next? The FORUM consortium is expanding research to other cancer types and countries to better understand RWE transportability. Future studies will focus on comparing outcomes across diverse healthcare systems, identifying key variables for adjustment and developing guidelines for when and how non-local data can be used. These efforts aim to create a framework for the use of global RWE in oncology HTA decision-making.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Technology Assessment, BiomedicalMedical OncologyNeoplasmsHumansUnited States

Stichwörter der Autor:innen

HTARWEhealth technology assessmentreal-world evidencetransportability

Autor:innen und Institutionen

  • Flatiron Health UK, London, UK.
  • Roche, Basel, Switzerland.
  • Pfizer, New York City, NY 10001, USA.
  • Gilead, London, UK.
  • Daiichi Sankyo Europe GmbH, Munich, Germany.
  • Flatiron Health, New York, NY 10013, USA.

ORCID-Profile: Blythe Adamson

Zitieren

APA

Clunie-O'Connor, C., Thuresson, P. O., Masters, E., Taylor, A., Rosenlund, M., Mpofu, P., & Adamson, B. (2025). Crossing borders: the need for empirical evidence of real-world evidence transportability in oncology. Journal of Comparative Effectiveness Research. https://doi.org/10.57264/cer-2025-0053

Vancouver

Clunie-O'Connor C, Thuresson PO, Masters E, Taylor A, Rosenlund M, Mpofu P, et al. Crossing borders: the need for empirical evidence of real-world evidence transportability in oncology. Journal of Comparative Effectiveness Research. 2025. doi:10.57264/cer-2025-0053

BibTeX
@article{ClunieOConnor2025,
  author = {Clunie-O'Connor, Caitlin and Thuresson, Per-Olof and Masters, Elizabeth and Taylor, Aliki and Rosenlund, Mats and Mpofu, Philani and Adamson, Blythe},
  title = {Crossing borders: the need for empirical evidence of real-world evidence transportability in oncology},
  journal = {Journal of Comparative Effectiveness Research},
  year = {2025},
  doi = {10.57264/cer-2025-0053}
}
Kostenlos starten →